Similarly, it has been described that the inhibitory receptor CD22 (Siglec‐2) is expressed at lower levels on CLL cells than on normal naïve human B cells (Jasper et al, 2011; Salem & Stetler‐Stevenson, 2019). The gene discussed is CD22; the disease is B-cell chronic lymphocytic leukemia.